Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?
1 other identifier
interventional
100
1 country
1
Brief Summary
patients will be divided into two equal groups, each group including 50 adult patients with a confirmed diagnosis of covid, patients with acute kidney injury, the first group will be treated with early hemodialysis, second group will be conservative until there is an urgent need for dialysis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
March 9, 2022
CompletedFirst Posted
Study publicly available on registry
March 10, 2022
CompletedMarch 10, 2022
February 1, 2022
6 months
March 9, 2022
March 9, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
reduction of Sequential Organ Failure Assessment Score
prevention of multi-organ failure associated with covid including respiratorym circulatory, liver and renal failure
2 weeks
Study Arms (2)
covid positive with acute kidney injury receiving early renal replacement
EXPERIMENTALcovid positive with acute kidney injury under conservative management
EXPERIMENTALInterventions
continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
Eligibility Criteria
You may qualify if:
- adult patients (≥18 years old) with confirmed severe acute respiratory syndrome coronavirus 2 infections admitted to the ICU.
You may not qualify if:
- Malignancy.
- Immuno-deficiency diseases.
- Chronic diabetic, cardiac and hypertensive patients
- autoimmune diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Faculty of Medicine, Sohag University
Sohag, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of anesthesia and intensive care
Study Record Dates
First Submitted
March 9, 2022
First Posted
March 10, 2022
Study Start
June 1, 2021
Primary Completion
December 1, 2021
Study Completion
January 1, 2022
Last Updated
March 10, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share